Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger reiterates a Buy rating on KalVista Pharma (NASDAQ:KALV) and maintains a $35 price target.
June 18, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on KalVista Pharma and maintains a $35 price target.
The reiteration of a Buy rating and the maintenance of a $35 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100